Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab with Radiation Therapy for HER2-Positive DCIS (NSABP B-43)
NCT00769379Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2008
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in ductal carcinoma in situ (DCIS) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival at 5 years. Started Dec 2008; status: completed.
02
Drugs
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT00769379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00769379.